Objective
The unifying aim of VIROMARKERS is to define virus related biomarkers to improve management of chronic diseases, including biomarkers of response to antiviral treatment of persistent viral infections and virome features as indicators of disease progression in immunosuppressed people.
The project has the following objectives:
1. To demonstrate a novel bioinformatics method for prediction of HIV-1 susceptibility to broadly neutralising antibodies based on the HIV-1 gp120 sequence.
2. To demonstrate novel HDV biomarkers (HDV-RNA, HBsAg isoforms and HDV genotype) to predict treatment response to the recently approved anti-HDV bulevirtide.
3. To validate serum CMV-RNA as a biomarker of CMV infection/reactivation to optimise the correct timing for preventive strategies in patients undergoing hematopoietic stem cell transplantation.
4. To validate the torque teno virus DNA as a prognostic biomarker for CMV disease in immunocompromised patients.
5. To validate total and intact cellular HIV DNA as a biomarker of HIV infection status to guide novel antiviral strategies.
Validation or demonstration of several technologies required to measure the candidate biomarkers is an integral part of the project objectives. In particular, this refers to the following diagnostic tools:
• dPCR as a tool for HDV quantification
• NGS platform for HDV sequencing
• qPCR diagnostics for CMV-RNA quantification
• IPDA suitable for detection of intact HIV-DNA in any viral subtype
• qPCR diagnostics for TTV-DNA
Leveraging on the regulatory expertise present in the consortium, VIROMARKERS will define the regulatory pathway for each of its outcomes and will generate the experimental data necessary to move prototype methods and tools to regulatory approval.
Overall, VIROMARKERS, with its public private partnership nature, will make available for healthcare providers and for researchers robust and fit-for-purpose biomarkers and linked technologies enabling their clinical use in response to important unmet clinical needs with, in the end, an important impact also for patients.
VIROMARKERS is supported by the Innovative Health Initiative Joint Undertaking (IHI JU). The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, and Vaccines Europe
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencesbiological sciencesmicrobiologyvirology
- natural sciencesbiological sciencesgeneticsDNA
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesclinical medicinetransplantation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback.
You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Programme(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.7 - Innovative Health Initiative
Funding Scheme
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinator
00152 Roma Rm
Italy
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participants (19)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
00152 Roma
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
17177 Stockholm
See on map
53100 Siena
See on map
50937 Koeln
See on map
63225 Langen
See on map
00133 Roma
See on map
20142 Milano
See on map
40225 Dusseldorf
See on map
1050 Bruxelles / Brussel
See on map
40237 DUSSELDORF
See on map
WC1E 6BT London
See on map
20122 Milano
See on map
13347 Berlin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
22767 Hamburg
See on map
04129 LEIPZIG
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
61030 Cartoceto
See on map
00167 Roma
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
50131 Firenze
See on map
40724 Hilden
See on map